AVALYN PHARMA INC (AVLN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$37.39+5.50%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · AVLN
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue enrollment and data generation for AP01 Phase 2b, AP02 Phase 2, and initiate AP03 Phase 1 trials to develop inhaled antifibrotic therapies.
Newly stated in 2026-Q2. Management reported completion of enrollment for the AP01 MIST Phase 2b trial with 398 patients, exceeding the target of 375, and that AP02 enrollment is on track for 160 patients. The AP03 Phase 1 study is planned to initiate by end of 2026. These clinical development activities are progressing as planned, indicating delivery on stated growth priorities.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Not enough signal yet.
Not enough signal yet.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates (low R² over the window).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Completed enrollment of MIST global Phase 2b trial of AP01 with 398 patients; AP02 enrollment on track; AP03 Phase 1 study on track to initiate by end of 2026.”
Preserve cash, cash equivalents, and marketable securities to support ongoing clinical development and operations through 2029.
Newly stated in 2026-Q2. The company ended Q2 2026 with $413.5 million in cash and equivalents, a substantial increase from prior periods due to IPO proceeds, supporting a cash runway projected into 2029. This financial position aligns with management's stated priority to maintain funding for operations and clinical programs.
“Ended the second quarter of 2026 with $413.5 million in cash, cash equivalents and marketable securities; cash runway projected into 2029.”
Increase leased space by amending sublease agreement with CRISPR Therapeutics to support operational growth.
Newly stated in 2026-Q2. Management executed a sublease amendment adding 8,774 rentable square feet to support operational expansion. This facility expansion is a concrete step toward growth, consistent with prior stated intentions.
“Entered into a First Amendment to the Sublease Agreement with CRISPR Therapeutics, adding approximately 8,774 rentable square feet.”
Control research and development and general administrative expenses while advancing clinical trials.
Newly stated in 2026-Q2. Operating expenses increased with R&D rising from $17.9M to $24.7M and G&A from $3.9M to $6.6M year-over-year, reflecting expanded clinical activity and personnel. Management is managing expenses consistent with growth in clinical programs, indicating controlled cost increases aligned with development priorities.
“R&D expenses $24.7M and G&A expenses $6.6M in Q2 2026, increases driven by clinical trials and personnel costs.”
1 material management or governance event in the past 24 months, led by M&A activity. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.